Todd Asset Management LLC Purchases Shares of 2,642,588 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Todd Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,642,588 shares of the company’s stock, valued at approximately $58,243,000. Teva Pharmaceutical Industries makes up approximately 1.4% of Todd Asset Management LLC’s holdings, making the stock its 14th largest holding. Todd Asset Management LLC owned about 0.23% of Teva Pharmaceutical Industries at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smithfield Trust Co lifted its position in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $50,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $66,000. Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $60,000. Finally, IFP Advisors Inc lifted its position in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.0 %

TEVA stock opened at $16.75 on Tuesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The firm has a fifty day moving average price of $19.93 and a two-hundred day moving average price of $18.50. The firm has a market cap of $18.97 billion, a price-to-earnings ratio of -11.55, a PEG ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analysts Set New Price Targets

TEVA has been the topic of a number of recent research reports. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.